217817-01-1

Basic information

• Product Name: Tos-PEG4-t-butyl ester
• Synonyms: Tos-PEG4-t-butyl ester;Tos-PEG3-CH2CH2COOtBu
• CAS NO: 217817-01-1
• Molecular Formula: C₂₀H₃₂O₈S
• Molecular Weight: 432.52828
• Mol File: 217817-01-1.mol

Chemical Properties

• Boiling Point: 528.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.154±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Tos-PEG4-t-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Tos-PEG4-t-butyl ester(217817-01-1)
• EPA Substance Registry System: Tos-PEG4-t-butyl ester(217817-01-1)

Safety Data

• Hazardous Substances Data: 217817-01-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tos-PEG4-t-butyl ester is used as a molecular building block for the development of pharmaceutical compounds. Its hydrophilic PEG spacer and t-butyl protected carboxyl group enable the creation of water-soluble drug conjugates, improving the pharmacokinetic properties and bioavailability of the final product.
Used in Chemical Synthesis:
In the field of chemical synthesis, Tos-PEG4-t-butyl ester is used as a versatile intermediate for the synthesis of various complex molecules. The tosyl group's reactivity as a leaving group in nucleophilic substitution reactions allows for the selective introduction of different functional groups, facilitating the construction of diverse chemical libraries.
Used in Bioconjugation:
Tos-PEG4-t-butyl ester is used as a bioconjugation agent to attach biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The hydrophilic PEG spacer and t-butyl protected carboxyl group provide a stable and functional platform for the covalent attachment of these biomolecules, enhancing their stability, solubility, and bioactivity.
Used in Drug Delivery Systems:
In the development of drug delivery systems, Tos-PEG4-t-butyl ester is used as a component in the design of targeted drug carriers. The PEG spacer and t-butyl ester can be utilized to improve the solubility and circulation time of drug-loaded nanoparticles or liposomes, while the tosyl group can be employed for the attachment of targeting ligands, enabling selective drug delivery to specific cells or tissues.
Used in Material Science:
In the field of material science, Tos-PEG4-t-butyl ester is used as a component in the development of novel materials with tailored properties. The hydrophilic PEG spacer and t-butyl protected carboxyl group can be incorporated into polymers, gels, or other materials to enhance their solubility, biocompatibility, and responsiveness to environmental stimuli.

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 186020-66-6 3-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-propionic acid tert-butyl ester 
• 1663-39-4 tert-Butyl acrylate 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 104-15-4 toluene-4-sulfonic acid 

Downstream Products

• 919367-04-7 1,4-dibromo-2,5-bis(11-(tert-butoxycarbonyl)-3,6,9-trioxahendecyloxy)benzene 
• 1274917-85-9 C₄₂H₇₀O₁₂Si₂ 
• 1274917-81-5 C₃₆H₅₄O₁₂ 
• 1274917-84-8 1,4-diiodo-2,5-bis(11-(tert-butoxycarbonyl)-3,6,9-trioxaundecyloxy)benzene 
• 1354653-07-8 C₄₄H₅₄N₆O₈ 
• 1354652-69-9 C₄₀H₄₆N₆O₈ 
• 1354652-71-3 2-oxo-1-(3-((3-((2-((5-phenylpyrimidin-2-yl)carbamoyl)-4-(piperidin-1-yl)-phenyl)carbamoyl)benzyl)thio)phenyl)-6,9,12-trioxa-3-azapentadecan-15-oic acid 
• 935272-06-3 1,4-diiodo-2,5-bis(11-carboxy-3,6,9-trioxaundecyloxy)benzene 
• 1814901-03-5 aminobis(4,7,10-trioxadodecanoic acid tert-butyl ester) 

Relevant articles and documents

CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS

Provided are conjugates of camptothecin analogs with a cell-binding molecule of formula (I), wherein R1, R2, R3, R4, R5, X, L, n, m, T and ----- are defined herein. It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of using the conjugates in targeted treatment of cancer, infection, and immunological disorders.

Quinazoline derivative capable of activating targeted ubiquitination to degrade EGFR (epidermal growth factor receptor) protein through hypoxia reduction and application of quinazoline derivative

The invention belongs to the field of medicinal chemistry, and particularly relates to quinazoline derivatives, the structure of which is shown as follows: R1, R2 and R3 are respectively and independently selected from hydrogen, chlorine, fluorine, bromin

Quinazoline derivative containing 2-nitroimidazole and application of quinazoline derivative

The invention belongs to the field of medicinal chemistry, and particularly relates to a quinazoline derivative of 2-nitroimidazole. The quinazoline derivative has a structure as shown in the specification, wherein R1 and R2 are respectively and independe

Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders

Histone H3K4 methylation serves as a post-translational hallmark of actively transcribed genes and is introduced by histone methyltransferase (HMT) and its regulatory scaffolding proteins. One of these is the WD-repeat-containing protein 5 (WDR5) that has also been associated with controlling long noncoding RNAs and transcription factors including MYC. The wide influence of dysfunctional HMT complexes and the typically upregulated MYC levels in diverse tumor types suggested WDR5 as an attractive drug target. Indeed, protein-protein interface inhibitors for two protein interaction interfaces on WDR5 have been developed. While such compounds only inhibit a subset of WDR5 interactions, chemically induced proteasomal degradation of WDR5 might represent an elegant way to target all oncogenic functions. This study presents the design, synthesis, and evaluation of two diverse WDR5 degrader series based on two WIN site binding scaffolds and shows that linker nature and length strongly influence degradation efficacy.

A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS

The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.

A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS

Provided is a conjugation of cytotoxic drug to a cell-binding molecule with a side-chain linker. It provides side-chain linkage methods of making a conjugate of a cytotoxic molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and immunological disorders.

CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES

A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS

Provided herein is the conjugation of an amanita toxin compound to a cell-binding molecule with branched linkers for having better targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of an amanita molecule to a cell-binding ligand, as well as methods of using the conjugate in targets treatment of cancer, infection and autoimmune disease.

Systematic Investigation of the Permeability of Androgen Receptor PROTACs

Bifunctional molecules known as PROTACs simultaneously bind an E3 ligase and a protein of interest to direct ubiquitination and clearance of that protein, and they have emerged in the past decade as an exciting new paradigm in drug discovery. In order to investigate the permeability and properties of these large molecules, we synthesized two panels of PROTAC molecules, constructed from a range of protein-target ligands, linkers, and E3 ligase ligands. The androgen receptor, which is a well-studied protein in the PROTAC field was used as a model system. The physicochemical properties and permeability of PROTACs are discussed.